Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) fell 4.2% during mid-day trading on Thursday . The company traded as low as $4.52 and last traded at $4.52, with a volume of 1,275,372 shares changing hands. The stock had previously closed at $4.72.

A number of research firms have recently issued reports on KERX. Cowen and Company reiterated a “hold” rating on shares of Keryx Biopharmaceuticals in a research report on Saturday, April 30th. Morgan Stanley reiterated a “hold” rating on shares of Keryx Biopharmaceuticals in a research report on Saturday, April 30th. FBR & Co reiterated a “buy” rating and set a $13.00 price target on shares of Keryx Biopharmaceuticals in a research report on Friday, April 29th. Zacks Investment Research downgraded shares of Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, August 3rd. Finally, Stifel Nicolaus downgraded shares of Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 2nd. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $7.75.

The firm’s 50-day moving average is $5.70 and its 200 day moving average is $5.31. The firm’s market capitalization is $483.94 million.

Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings data on Monday, August 1st. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.14. During the same period in the previous year, the business earned ($0.26) EPS. The firm had revenue of $9.30 million for the quarter, compared to analyst estimates of $8.60 million. Keryx Biopharmaceuticals’s quarterly revenue was up 272.0% on a year-over-year basis. Analysts anticipate that Keryx Biopharmaceuticals Inc. will post ($1.23) earnings per share for the current fiscal year.

In other news, CFO Scott A. Holmes sold 4,935 shares of the stock in a transaction that occurred on Friday, July 29th. The shares were sold at an average price of $7.36, for a total value of $36,321.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

A hedge fund recently raised its stake in Keryx Biopharmaceuticals stock. Schwab Charles Investment Management Inc. increased its stake in shares of Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) by 3.7% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 375,655 shares of the biopharmaceutical company’s stock after buying an additional 13,405 shares during the period. Schwab Charles Investment Management Inc. owned 0.36% of Keryx Biopharmaceuticals worth $1,898,000 at the end of the most recent reporting period.

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.